The latest price target for Pliant Therapeutics (NASDAQ:PLRX) was reported by Canaccord Genuity on March 13, 2026. The analyst firm set a price target for $3.00 expecting PLRX to rise to within 12 months (a possible 156.41% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Pliant Therapeutics (NASDAQ:PLRX) was provided by Canaccord Genuity, and Pliant Therapeutics maintained their hold rating.

There is no last upgrade for Pliant Therapeutics

The last downgrade for Pliant Therapeutics Inc happened on October 10, 2025 when JP Morgan changed their price target from N/A to N/A for Pliant Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pliant Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pliant Therapeutics was filed on March 13, 2026 so you should expect the next rating to be made available sometime around March 13, 2027.

While ratings are subjective and will change, the latest Pliant Therapeutics (PLRX) rating was a maintained with a price target of $4.00 to $3.00. The current price Pliant Therapeutics (PLRX) is trading at is $1.17, which is out of the analyst’s predicted range.